Does Wellcare Cover Wegovy?

No. Medicare Part D cannot cover any drug for weight loss — this is a federal statute that applies to all Medicare plans including every Wellcare Part D plan. Starting July 1, 2026, the Medicare GLP-1 Bridge provides eligible Wellcare beneficiaries access to Wegovy for weight loss at $50 per month outside Part D through December 31, 2027. If you have established cardiovascular disease, the CV indication is a separate coverage path under Part D that predates the Bridge.

Wellcare is a participating plan in the Medicare GLP-1 Bridge program, which launches July 1, 2026. Eligible beneficiaries pay a fixed $50 per month copay for Wegovy weight-loss access. The Bridge operates outside Part D, so the $50 does not count toward your deductible, TrOOP, or the $2,100 OOP cap, and Extra Help cannot be applied. Eligibility requires provider attestation of qualifying BMI criteria. Members already on a Part D-covered GLP-1 are not eligible. Note: Humana — not Wellcare — is the CMS-selected central processor administering the Bridge.

Both Humana and Wellcare are Medicare-first plans where the Part D statutory exclusion and Bridge are the operative story. The key distinction is that Humana is the CMS-selected central processor for the entire Medicare GLP-1 Bridge program — giving the Humana page program-administration authority. Wellcare is a participating plan in the Bridge, not its administrator. Both pages cover the same Medicare coverage logic, but Humana's role in running the Bridge is a unique operational fact that does not apply to Wellcare.

Only in states whose Medicaid program covers GLP-1s for obesity — 13 states as of January 2026. Wellcare operates Medicaid managed-care plans across multiple states. Whether your specific state's Medicaid program covers Wegovy for obesity is a state-government decision, not a Wellcare decision. Verify on your state-specific Wellcare Medicaid formulary. The cardiovascular indication is covered across states for qualifying members.

No. The NovoCare Wegovy Savings Offer (as little as $25 per month, max $100 per 28-day supply) is not available to Medicare or Medicaid beneficiaries due to federal anti-kickback rules. Because Wellcare's membership is predominantly Medicare Part D and Medicaid, the savings card is generally not applicable. Commercially insured Wellcare members whose plan covers Wegovy may be eligible; verify at novocare.com.

Two significant pricing changes take effect January 1, 2027. Novo Nordisk has announced it will reduce Wegovy's list price to approximately $675 per month. The IRA-negotiated Maximum Fair Price for semaglutide of $274 per 30-day supply also takes effect for Medicare. For Wellcare Medicare beneficiaries, the MFP may meaningfully reduce out-of-pocket costs for the CV indication after the $2,100 cap is reached. The Medicare Bridge's $50 per month copay and its terms through December 2027 remain as currently announced.